• Publications
  • Influence
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale.
There is no difference in ORR, TTP, and OS for patients treated with the FOLFIRI or FOLFOX4 regimen, and both therapies seemed effective as first-line treatment in these patients.
A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following
This Phase III study demonstrated the superiority of NEPA compared with PALO and delivered antiemetic guideline-recommended prophylaxis by targeting two critical molecular pathways associated with chemotherapy-induced nausea/vomiting.
Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging.
Weak protein binding can substantially increase the efficacy of gadolinium chelates as general purpose contrast agents for MRI.
Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer.
In elderly patients with NSCLC, G + V treatment is associated with significantly better survival than is V alone, and a clear delay in symptom and QoL deterioration.
Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a
The PGV regimen is associated with a substantial survival gain (MST > 3 months longer) when compared with the PV combination, and the accrual in the PV arm has been stopped (null hypothesis rejected).